Latest MXCT news and sentiment

MaxCyte launches CHANGE-seq-BE and ONE-seq-BE to strengthen off-target assessment for genome editing therapies

MaxCyte has introduced CHANGE-seq-BE and ONE-seq-BE, new off-target nomination assays available through its SeQure service. These assays are designed to improve the assessment of off-target effects for adenine- and cytosine-base editors (ABEs and CBEs) in genome editing therapies. The launch addresses evolving regulatory expectations for sensitive and orthogonal off-target assessment methods as base editing therapies advance toward clinical application.

MaxCyte Gets A Genentech Nod, But Revenue Still Comes In Chunks

MaxCyte (NASDAQ: MXCT), a cell-engineering company, has reiterated its 2026 revenue guidance of $30-$32 million, driven by high-margin consumables and Strategic Platform License (SPL) milestones. The company recently secured a multi-platform technology license partnership with Genentech, boosting its credibility and potential for enterprise deals. Despite this positive development, MaxCyte continues to face challenges such as lumpy SPL revenue, ongoing operating losses, and high stock volatility.

MaxCyte (MXCT) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 12, 2026 at 4:30 p.m. ET CALL PARTICIPANTS President and Chief Executive Officer-Maher Masoud Chief Financial Officer-Parmeet Ahuja Senior Director of Business Development-Sean Menarguez Investor Relations-Erik Abdo Full Conference Call Transcript Operator: Good day. Thank you for standing by. Welcome to the MaxCyte Second Quarter Earnings Conference Call. At this time, all-- After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press star-11 on your telephone. Yo

MaxCyte launches CHANGE-seq-BE™ and ONE-seq-BE™ to strengthen off-target assessment for genome editing therapies

MaxCyte (NASDAQ: MXCT) has launched two new off-target nomination assays, CHANGE-seq-BE™ and ONE-seq-BE™, for adenine and cytosine base editors, offered through its SeQure™ gene editing risk assessment service. These assays aim to provide sensitive and unbiased biochemical assessment of off-target sites, with ONE-seq-BE uniquely offering visibility into population-specific genetic variants that could influence off-target activity. The company states that these tools will help therapeutic developers align with evolving regulatory expectations, including recent FDA guidance on genome safety, by building stronger data packages for clinical development.

MaxCyte launches base editor off-target nomination assays

MaxCyte Inc. (NASDAQ:MXCT) has introduced two new off-target nomination assays, CHANGE-seq-BE and ONE-seq-BE, for base editors through its SeQure service. These assays are designed to help therapeutic developers identify and prioritize off-target sites, aligning with regulatory guidance like that from the FDA on genome editing safety. The company aims to provide sensitive and orthogonal assessment capabilities to mitigate off-target risks in clinical development.

MaxCyte, Inc. Revenue Breakdown – NASDAQ:MXCT

MaxCyte, Inc. (NASDAQ: MXCT) generated $33.03 million USD in revenue last year. Its top-performing segment, PA Revenue, contributed $11.89 million USD, a decrease from the $14.01 million USD in the previous year. The United States was the largest regional contributor, accounting for $21.08 million USD of the revenue.

Teleconferência de Resultados do 2T26 da MaxCyte (MXCT): Guidance Reafirmado com a Expansão da Parceria com a Genentech

MaxCyte reported Q2 2026 total revenue of $7.3 million, a 15% year-over-year decrease but exceeding expectations due to sequential growth in instrument allocations and processing assembly demand. The company reaffirmed its full-year revenue guidance of $30 million to $32 million, anticipating low single-digit growth in the second half of the year. A new multi-platform partnership with Genentech and a strong cash position of $141.9 million underpin its strategic focus and ongoing share repurchase program.

Conferencia de resultados del T2 de 2026 de MaxCyte (MXCT): Se reafirman las proyecciones a medida que se amplía la alianza con Genentech

MaxCyte (MXCT) reportó ingresos totales de $7.3 millones en el segundo trimestre de 2026, una disminución del 15% interanual, pero reafirmó sus proyecciones anuales de ingresos entre $30 y $32 millones. La empresa destacó una nueva alianza multiplataforma con Genentech, que abarca múltiples programas desde investigación hasta fabricación cGMP, y la adopción de su tecnología DTx. MaxCyte finalizó el trimestre con $141.9 millones en efectivo y sin deuda, priorizando el crecimiento orgánico y la recompra de acciones.

Price to sales forward of MaxCyte, Inc. – MUN:MYE0

This page from TradingView provides financial information for MaxCyte, Inc. (MUN:MYE0), specifically focusing on its forward price-to-sales ratio. The article indicates that market data is provided by ICE Data Services and reference data by FactSet, with SEC filings from Quartr.

MaxCyte Q2 Results: EPS beats estimates, revenue falls 14.5% YoY

MaxCyte Inc. reported Q2 2026 results, with EPS beating estimates at $(0.08) despite a 14.53% year-over-year revenue decrease to $7.271 million. The company narrowed its net loss by 33.33% and announced a new strategic partnership with Genentech. MaxCyte also reaffirmed its full-year 2026 revenue guidance of $30-32 million, maintaining stability in its outlook.

MaxCyte (MXCT) Earnings Call Signals Stabilizing Turnaround

$MXCT ($MXCT) Releases Q2 2026 Earnings

MaxCyte Reports Second Quarter 2026 Financial Results

MaxCyte, Inc. announced its financial results for the second quarter ended June 30, 2026, reporting total revenue of $7.3 million, a 15% decrease year-over-year, and a net loss of $8.9 million, an improvement from the $12.4 million loss in Q2 2025. The company reiterated its full-year 2026 revenue guidance of $30 million to $32 million and highlighted a new multi-platform technology license partnership with Genentech. MaxCyte also noted the repurchase of approximately $5.5 million of common stock under its authorized $10 million share repurchase program.

Tranche Update on MaxCyte, Inc.'s Equity Buyback Plan announced on May 12, 2026.

MaxCyte, Inc. has provided an update on its equity buyback plan announced on May 12, 2026. As of August 12, 2026, the company has repurchased 4,730,105 shares, representing 4.42% of its stock, for a total of $5.5 million. This repurchase completes the program initiated earlier in the year.